| 摘要 |
Contemplated antiviral composition and method of treatment of a patient include administration of a pharmaceutical composition that comprises a first nucleoside analog in an amount effective to change expression of at least one of a Th1 cytokine and a Th2 cytokine, a second nucleoside that exhibits organ-specific antiviral activity, and optionally a cytokine. Still further contemplated compositions may comprise a biological structure to which an antiviral drug is coupled, wherein the half-life time of the biological structure is greater than the half-life time of the antiviral drug, and wherein the antiviral drug is present in the composition in an amount of at least 1000 mg.
|
